Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

NCT04645160 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

31

Enrollment

NIH

Sponsor class

Conditions

Cholangiocarcinoma
Bile Duct Neoplasm
Biliary Tract Malignancy

Interventions

DRUG: Tivozanib

Sponsor

National Cancer Institute (NCI)